HomeCompareASXC vs EPRT

ASXC vs EPRT: Dividend Comparison 2026

ASXC yields 574.88% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASXC wins by $183655.91M in total portfolio value
10 years
ASXC
ASXC
● Live price
574.88%
Share price
$0.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183655.98M
Annual income
$136,833,479,194.82
Full ASXC calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ASXC vs EPRT

📍 ASXC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASXCEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASXC + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASXC pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASXC
Annual income on $10K today (after 15% tax)
$48,864.62/yr
After 10yr DRIP, annual income (after tax)
$116,308,457,315.60/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ASXC beats the other by $116,308,446,400.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASXC + EPRT for your $10,000?

ASXC: 50%EPRT: 50%
100% EPRT50/50100% ASXC
Portfolio after 10yr
$91828.02M
Annual income
$68,416,746,017.77/yr
Blended yield
74.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ASXC
Analyst Ratings
2
Hold
Consensus: Hold
Price Target
$1.50
+331.2% upside vs current
Range: $1.50 — $1.50
Altman Z
-41.9
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASXC buys
0
EPRT buys
0
No recent congressional trades found for ASXC or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASXCEPRT
Forward yield574.88%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$183655.98M$63.4K
Annual income after 10y$136,833,479,194.82$12,840.73
Total dividends collected$179712.33M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$1.50$35.50

Year-by-year: ASXC vs EPRT ($10,000, DRIP)

YearASXC PortfolioASXC Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$68,188$57,487.78$11,205$505.18+$57.0KASXC
2$439,313$366,351.83$12,672$682.46+$426.6KASXC
3$2,675,944$2,205,879.72$14,490$930.48+$2.66MASXC
4$15,420,706$12,557,445.87$16,786$1,282.69+$15.40MASXC
5$84,130,987$67,630,830.90$19,753$1,791.56+$84.11MASXC
6$434,856,205$344,836,049.27$23,677$2,541.64+$434.83MASXC
7$2,131,079,702$1,665,783,562.49$29,008$3,672.99+$2131.05MASXC
8$9,909,627,711$7,629,372,430.43$36,463$5,425.08+$9909.59MASXC
9$43,759,343,910$33,156,042,258.68$47,238$8,221.57+$43759.30MASXC
10$183,655,977,178$136,833,479,194.82$63,385$12,840.73+$183655.91MASXC

ASXC vs EPRT: Complete Analysis 2026

ASXCStock

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Full ASXC Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ASXC vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASXC vs SCHDASXC vs JEPIASXC vs OASXC vs KOASXC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.